<DOC>
	<DOCNO>NCT00360126</DOCNO>
	<brief_summary>The precursor study ( SCA101469 ) open-label , prospective multicentre study adult subject diagnose bipolar disorder consist 36 week treatment lamotrigine . The current study provide 12 month post study access open-label lamotrigine participant SCA101469 study .</brief_summary>
	<brief_title>An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : complete 32 week open label treatment study SCA101469 , investigator opinion , respond lamotrigine therapy male female subject A female eligible enter participate study : 1. nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal sterilise ) , 2. childbearing potential , negative urine pregnancy test screening , agree one follow contraceptive method : Complete abstinence intercourse 2 week prior administration study drug , throughout study , time interval completion premature discontinuation study account elimination investigational drug ( minimum 5 halflives longer pharmacodynamic profile investigational drug warrant long time period ) ; , Sterilisation male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combine progestogen ) ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Any method publish data show low expected failure rate method le 1 % per year ; , Barrier method use combination acceptable method . willing able give write informed consent participate study . A subject eligible inclusion study follow criterion apply : subject experience 'mood episode ' participation study SCA101469 , since complete participation study SCA101469 . participation clinical drug trial SCA101469 within past 30 day previous participation clinical study know hypersensitivity lamotrigine investigator 's judgement , subject pose current serious suicidal homicidal risk , make suicide attempt within past 6 month . combination carbamazepine valproate concurrent lamotrigine therapy , commence study SCA101469 current history substance abuse diagnosis epilepsy diagnosis history obsessivecompulsive disorder , social phobia , eat disorder significant cardiac , renal , cerebrovascular , hepatic condition ; significant abnormality laboratory test ECG record perform study SCA101469 . unable understand implement instruction unresolved drug relate adverse event serious adverse event occur study SCA101469</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lamictal</keyword>
	<keyword>lamotrigine</keyword>
	<keyword>Open-Label Extension Study</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>